British stocks have touched new highs in 2026, shrugging off a backdrop of geopolitical tension and global economic uncertainty that has rattled other developed markets. The FTSE 100 hit an all-time high of 10,934.94 in February, and although it has pulled back to 10,379 points as of 24 April, the index has outperformed both the UK’s sluggish economic fundamentals and the broader political headwinds that have kept many international investors on the sidelines. The resilience is not confined to large caps: the FTSE 250 has also shown surprising strength, driven by a rotation into value stocks and sustained interest from private equity in mid-cap names trading at depressed valuations. The UK’s outperformance rests partly on the modest starting prices of its companies and a preponderance of cash-generative businesses that can weather downturns. Yet a deputy governor of the Bank of England has warned that record-high global stock markets may be overstating risks and could be due for an “adjustment,” citing elevated private credit and highly valued AI stocks.
Croda: a contrarian bet on chemicals
Among the stocks analysts believe the market is overlooking is Croda (LSE: CRDA), the FTSE 100 speciality chemicals company that has endured a prolonged period of deep underperformance. The business, first listed on the London Stock Exchange in 1964, historically commanded high margins, robust growth and attractive returns, but a convergence of challenges — tough end markets and heavy investment in new pharmaceutical-oriented capabilities that have yet to pay off — undermined that reputation. Despite this, the company reiterated its full-year outlook in late March 2026, having raised prices to offset rising costs, and has implemented an ambitious cost-reduction programme that management believes will drive substantial improvements in profitability once demand recovers. Analysts remain cautious: UBS lowered its price target to £43.60 from £44.50, and Jefferies downgraded Croda to “hold” from “buy.” Nonetheless, a “Moderate Buy” consensus rating stands as of April 2026, and insider buying by former chief executive Steve Foots and Tom Brophy in March and April suggests confidence from those closest to the business. Jill Anderson was appointed as a non-executive director in January. The UK specialty chemicals market is projected to grow to $39.8bn by 2034, with Croda well placed in speciality surfactants and personal care active ingredients. For patient investors, the shares offer a dividend yield of more than 4% — a market-beating return while they wait for the turnaround to materialise.
WPP: a turnaround story at a rock-bottom price
WPP (LSE: WPP) has been one of the worst-performing stocks in the first quarter of 2026, with its shares down 30.81% over the period and 57.16% over the past year. Citigroup cut its price target to GBX 275, and the stock fell a further 5% on analyst downgrades. Yet the communications group is showing signs of a competitive resurgence. Under new leadership — including Cindy Rose appointed as chief executive — the company is consolidating its sprawling empire to leverage its talent and technology. For the last two consecutive quarters, WPP has led the market in winning new business, a reversal of its extended underperformance that supports the view it has turned a corner. In April, Anne-Isabelle Choueiri was named chief transformation officer. The company is integrating Google Earth AI into its WPP Open platform to deliver hyper-local marketing and physical-world media predictions, and it has launched “WPP Commerce” to centralise its commerce offering. WPP also continues to dominate the industry rankings, topping the WARC Media 100 for the ninth year running and the WARC Creative 100 for the fourth consecutive year. The UK advertising market is forecast to hit £45.4bn in 2025, with digital advertising accounting for around 83% of total spend in the second half of 2025. Despite the recent share-price weakness, WPP’s valuation is exceptionally undemanding: a price/earnings ratio of less than five times, and a dividend yield of well over 6% for the next year. The company’s balance sheet also carries ample cash, giving it strategic options at a time when the advertising industry is undergoing rapid technological change.
Chesnara: how a closed-book insurer delivers reliable cash and rising dividends
Of the three stocks, Chesnara (LSE: CSN) offers the most instructive example of how a disciplined acquisition strategy can generate predictable, long-term cash flows. The company is a lean, tightly run life-insurance and pension consolidator that specialises in buying closed life-insurance books — portfolios of policies that are no longer sold to new customers — often at substantial discounts to their book value. A seasoned management team then applies strict cost control and squeezes out business synergies, turning what might seem like tired legacy assets into engines of steady cash generation.
The result is a dividend record unmatched in UK and European insurance. Chesnara has increased its payout for 20 consecutive years, a feat that reflects the underlying reliability of the cash flows produced by its closed books. The model was supercharged last year by a transformational deal: the acquisition of HSBC Life (UK) for £260m, which received regulatory clearance in December 2025 and is expected to complete in early 2026. The transaction lifts Chesnara’s assets under administration by approximately £4bn to around £18bn and adds roughly 454,000 policies to its portfolio. It is projected to generate more than £800m in lifetime cash flows, with over £140m expected in the first five years alone. The increased scale and free float could also propel Chesnara into the FTSE 250 index, a milestone that would raise its profile among institutional investors. Chesnara has committed to maintaining the value-added services that HSBC Life UK provided to its customers after the deal closes.
The immediate benefit for shareholders was a one-off 6% dividend hike, and the company expects the acquisition to support a further 6% increase in its final FY25 and interim FY26 dividends. Even before the HSBC deal, Chesnara topped market forecasts with a £37m cash gain in its interim results, extending its 20-year run of dividend growth despite a dip in earnings. The group has a conservative balance sheet and a pipeline of further deals in sight, giving it the flexibility to repeat the playbook. The yield currently stands at more than 8%, making Chesnara a standout income play in a market where cash yields are hard to find. Risks remain: the Financial Conduct Authority has highlighted the challenges insurers face in complying with the Consumer Duty for closed products, and managing legacy IT systems and administrative costs is inherently complex. The company also issued £150m of convertible notes in July 2025 to help finance the acquisition. But for investors willing to accept the integration risks, the payoff could be substantial.
